contract_awardAwarded Monday, July 20, 2026Analyzed

HEALTH CARE AUTHORITY: $82.7M Department of Health and Human Services Grant

Neutral

Summary

This $82.7M grant from SAMHSA to the Washington State Health Care Authority funds opioid response initiatives including prevention, treatment, and recovery services. As the recipient is a state agency with no public parent company, there is no direct stock-level impact, though the grant signals continued federal prioritization of opioid crisis funding.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.The $82.7M SAMHSA grant to Washington State supports opioid prevention, treatment, and recovery, but has no direct publicly traded recipient.
  • 2.No related legislation in the provided list directly connects to this opioid response contract.
  • 3.Investors should monitor broader federal spending on addiction treatment as a sector tailwind, but this specific award does not create actionable stock-level catalysts.

Market Implications

As a grant to a state agency, this contract does not directly impact any publicly traded company's revenue or earnings. The broader healthcare sector, particularly companies involved in opioid addiction treatment (e.g., makers of buprenorphine, naloxone, and behavioral health platforms), may benefit indirectly from sustained federal focus, but no specific ticker movements can be tied to this award.

Full Analysis

The Substance Abuse and Mental Health Services Administration (SAMHSA) awarded an $82.7 million project grant to the Washington State Health Care Authority for the State Opioid Response (SOR) IV program. The grant supports a comprehensive response to the opioid epidemic, including community prevention coalitions, medication-assisted treatment (MOUD), harm reduction services, and recovery support. The award covers a three-year period from September 2024 to September 2027.

Because the recipient is a government agency and not a publicly traded company, no direct stock tickers are affected. However, this contract contributes to the broader healthcare sector's tailwind from sustained federal spending on addiction and mental health services. Companies providing opioid treatment medications (e.g., buprenorphine, naloxone) and behavioral health services may see indirect demand, but the connection is too diffuse for specific ticker attribution.

No related bills in the provided set directly authorized or appropriated funds for this specific grant. The listed bills cover diverse topics such as charter schools, Iran hostilities, and vehicle loan interest deductions, none of which align with the opioid response focus of this contract.

Downstream beneficiaries could include pharmaceutical manufacturers of addiction treatment drugs and tele-health platforms, but these are not identified as subcontractors in the award description. The grant's emphasis on harm reduction supplies and nicotine replacement therapy suggests potential demand for those product categories.

Historically, state opioid response grants have been renewed annually, providing consistent funding streams for public health agencies. Private-sector companies with exposure to opioid treatment markets often see steady, not volatile, revenue from such grants.

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderSep 18, 2026

Enhancing Program Integrity and Integrity and Interagency Coordination in the Administration of the H-1B Nonimmigrant Visa Program

This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.

proclamationSep 8, 2026

Accelerating Access To Veterans' Benefits And Employment Opportunities

This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.

Exec OrderAug 10, 2026

Delivering Gold Standard Childhood Vaccine Recommendations for Americans

This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.

Contract Details

Recipient

HEALTH CARE AUTHORITY

Award Amount

$82,727,977

Awarding Agency

Department of Health and Human Services

Sub-Agency

Substance Abuse and Mental Health Services Administration

Contract Type

PROJECT GRANT (B)

Free — no credit card

Get the next market-moving signal before the news does

HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.

Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.

Free forever plan · No credit card · Unsubscribe in one click

Want the live terminal too? Create a free account →